Navigation Links
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Date:8/17/2009

Cetrorelix pamoate is currently in three Phase 3 trials involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe.

The first Phase 3 efficacy trial Z-033, titled, "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1-year placebo-controlled efficacy study and long-term safety assessment", involved 667 patients mostly in North America and assessed an intermittent dosage regimen of cetrorelix as treatment for BPH-related signs and symptoms.

As announced recently, patients completing the 52 week double-blind study are then allowed to continue into an open-label extension of this study, sponsored by sanofi-aventis, where patients receive the same dosing regimen of cetrorelix by IM injection at Week 52, 54, 78 and 80, and are followed up to Week 90. Patients entering this extension study will be followed-up for safety, IPSS and quality of life, thus providing follow-up data on cetrorelix for up to 5 years.

The second multi-center Phase 3 efficacy study Z-036 for which patient recruitment was completed in October 2008, involves 420 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, M.D., of the Andros Mannenkliniek, Arnhem, The Netherlands, receive cetrorelix according to similar dosing regimens used in the first efficacy study Z-033.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include changes in sexual function. Other important endpoints include plasma changes in levels of testosterone, and assessment of other adverse events.

The third trial of the program is the safety study Z-041 titled, "Cet
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
2. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
3. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
6. AEterna Zentaris Receives US$10 Million from Institutional Investors
7. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
8. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
10. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
11. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Insero Health, Inc., a ... in epilepsy and related neurological disorders, is today reporting ... lead compound INS001 in patients with drug-resistant epilepsy.  The ... Device Trials (AED) Xll meeting by Dr. ... Chairman of Insero,s Scientific Advisory Board.  In this study, ...
(Date:5/17/2013)... RURO Inc. is pleased to announce ... refinement to the smart management solution. , ezColony, ... methodical management for transgenic animal colonies, genotyping and ... platform provides user access with a plethora of ... emphasize streamlined tasks, such as animal relocation to ...
(Date:5/17/2013)... 2013 Tooth decay is an epidemic in ... of the disease. The World Health Organization says that worldwide, ... adults have cavities. What are the long-term effects of this ... strong connection between the oral bacterial imbalance and serious systemic ... rampant, yet it is also 100% preventable? Answer: there has ...
(Date:5/16/2013)... Oven Industries, Inc. has been an industry leader ... since 1964. Expertly designed, the proportional-integral-derivative PID temperature ... As one of the most commonly used ... feedback system, which helps minimize errors. With three-term control, ... process, using a control element, like a valve or ...
Breaking Biology Technology:Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3New PID Temperature Controllers Announced by Oven Industries Inc. 2
... Ralph Kauten. Source: Teresa Esser. Ralph is one of ... of bioscience, said Frank Langley, president and CEO of Point ... Kauten to admit that his success in high-tech entrepreneurship is ... Kauten said in an interview. Ive been a lucky guy. ...
... the first debate of Wisconsin's U.S. Senate campaign, ... embryonic stem cells as little more than an inconsequential ... stem cell research that uses adult stem cells or ... uses human embryonic stem cells. , ,Technology is going ...
... innovative thinker has a lot of hard work to do ... at the Wisconsin Innovation Service Center s Ideas to ... ,Industry leaders, CEOs, lawyers and successful inventors came to share ... looking for a way to rise above the crowd. , ...
Cached Biology Technology:Ralph Kauten on how to raise angel financing 2Ralph Kauten on how to raise angel financing 3Ralph Kauten on how to raise angel financing 4It's 99 percent certain: Research cannot rely on adult stem cells alone 2It's 99 percent certain: Research cannot rely on adult stem cells alone 3More than ideas needed to make profits, experts say 2
(Date:5/16/2013)... can trigger hematopoiesis at sites outside the bone marrow ... of Ludwig-Maximilians-Universitaet (LMU) in Munich now show that a ... formation of blood cells. , Balanced hematopoiesis is essential ... development, hematopoiesis takes place mainly in the liver and ... bone marrow, and this tissue normally serves as the ...
(Date:5/16/2013)... around the world are meeting next week in ... showcase the latest in research findings about the ... understanding the disorders that affect them., "Canada is ... will showcase the best of neuroscience research done ... President of the Canadian Association for Neuroscience. He ...
(Date:5/16/2013)... us don,t ponder our pulses outside of the gym. But ... monitor heart health. , Zhenan Bao, a professor of chemical ... a dollar bill and no wider than a postage stamp. ... the wrist, is sensitive enough to help doctors detect stiff ... be used to continuously track heart health and provide doctors ...
Breaking Biology News(10 mins):Herpes infections: Natural killer cells activate hematopoiesis 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 3
... present in some living animal groups today has taken ... new evidence shows the feature is at least 100 ... Ludwig-Maximilians-Universitt Munich (Germany), has led an international team of ... collections. Their research has revealed fossilised evidence for reproduction ...
... Duke University have developed a laboratory robot that can successfully ... needle to its exact location - all without the need ... researchers to believe that in the future, such a robot ... but might also be used for such medical procedures as ...
... 18, 2009) - Omega-3 fatty acids found in fatty ... progression of age-related macular degeneration (AMD), but the benefits ... whether certain supplements are taken, report researchers at the ... USDA Human Nutrition Research Center on Aging (HNRCA) at ...
Cached Biology News:Size did matter 2Autonomous robot detects shrapnel 2Autonomous robot detects shrapnel 3Omega-3 fatty acids appear to impact AMD progression 2Omega-3 fatty acids appear to impact AMD progression 3
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... 2 - BSA and Azide free ... applications). Antigen: ... corresponding to C terminal amino acids ... Entrez GeneID: 2064 ...
Anti human PPAR gamma2 mouse monoclonal antibody...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Biology Products: